Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05343455 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)
A Phase 3 study of Papulopustular Rosacea, sponsored by Journey Medical Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 330
- Enrollment target
- 20
- Study locations
NCT05343455 is a Phase 3 study of Papulopustular Rosacea that has completed, run by Journey Medical Corporation. The registered enrollment target is 330 participants, above the 249-participant average among 11 other Papulopustular Rosacea trials with a reported enrollment target (33% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT05343455, a Phase 3 study of Papulopustular Rosacea, has completed, sponsored by Journey Medical Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 330 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a 16-week, multicenter, randomized, parallel-group, double-blind, controlled study. After assessing eligibility during a screening period of up to 30 days, approximately 320 subjects at least 18 years old who are diagnosed with moderate to severe papulopustular rosacea will be randomized in a 3:3:2 ratio to DFD-29 (40 mg), Doxycycline capsules 40 mg, or Placebo once daily for 16 weeks. Of the 320 subjects, approximately 160 subjects are planned to be enrolled at 15 sites in the US, while the remaining subjects are to be enrolled at 14 sites in the EU.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Doxycycline
- DRUG DFD-29
Study Locations (20)
Other
- Clinical Trial Site 17 - Bad Bentheim
- Clinical Trial Site 24 - Berlin
- Clinical Trial Site 22 - Bochum
- Clinical Trial Site 20 - Darmstadt
- Clinical Trial Site 25 - Dülmen
Florida
- Clinical Trial Site 01 - Doral
- Clinical Trial Site 02 - Miami
- Clinical Trial Site 14 - Miami
- Clinical Trial Site 05 - Miramar
Texas
- Clinical Trial Site 12 - Austin
- Clinical Trial Site 03 - Houston
- Clinical Trial Site 07 - Pflugerville
Indiana
- Clinical Trial Site 08 - Clarksville
- Clinical Trial Site 16 - Plainfield
Ohio
- Clinical Trial Site 09 - Cincinnati
- Clinical Trial Site 04 - Dublin
California
- Clinical Trial Site 15 - Santa Monica
Kentucky
- Clinical Trial Site 10 - Louisville
Missouri
- Clinical Trial Site 11 - Saint Joseph
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2022-03-29 |
| Est. Completion | 2023-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05343455
The ClinicalTrials.gov registry entry for NCT05343455 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 249-participant average among 11 other Papulopustular Rosacea trials with a reported enrollment target (33% higher). The listed sponsor is Journey Medical Corporation, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Papulopustular Rosacea appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05343455 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT05343455 about?
NCT05343455 is a clinical study titled "A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)". This is a 16-week, multicenter, randomized, parallel-group, double-blind, controlled study. After assessing eligibility during a screening period of up to 30 days, approximately 320 subjects at least 18 years old who are diagnosed with moderate to severe papulopustular rosacea will be randomized in ...
What is the current status of trial NCT05343455?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 330 participants. The study started on 2022-03-29. Estimated completion is 2023-06-30.
What conditions does trial NCT05343455 study?
This clinical trial studies the following conditions: Papulopustular Rosacea.
What interventions are being tested in trial NCT05343455?
The interventions under investigation include: Placebo (DRUG), Doxycycline (DRUG), DFD-29 (DRUG).
Who is sponsoring clinical trial NCT05343455?
This trial is sponsored by Journey Medical Corporation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05343455 being conducted?
This trial has 20 study locations across California, Florida, Indiana, Kentucky, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Papulopustular Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea
COMPLETED · Phase 3
-
A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
COMPLETED · Phase 3
-
Phase 3 Papulopustular Rosacea Study
COMPLETED · Phase 3
-
Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea
RECRUITING · Phase 2
-
Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties
COMPLETED · Phase 1
-
Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.